A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Active Systemic Lupus Erythematosus

In brief

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.

Key facts

Study ID

NCT07311200

Run by

InventisBio Co., Ltd

People needed

120

Starts

2026-02-12

Expected to finish

2028-12-31

Last updated by the study team

2026-04-24

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient voluntarily participates in this study after full informed consent.
• The age is 18 years ≤ age ≤ 70 years, regardless of gender.
• Diagnosed with Systemic Lupus Erythematosus (SLE) at least ≥ 24 weeks prior to screening.
• SLEDAI-2K total score ≥ 8.
• On stable treatment for systemic lupus erythematosus at least 4 weeks prior to randomization, and should remain at a stable dose throughout the trial period.

You may not qualify if…

• History of infection as defined in the protocol.
• Any of the medical diseases or disorders listed in the protocol.
• Significant, uncontrolled or unstable disease in any organ.

Where it is running

• Linfen Central Hospital — Linfen, Jiangxi, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.